Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Inventory Average (2022 - 2025)

BioXcel Therapeutics has reported Inventory Average over the past 4 years, most recently at $590500.0 for Q4 2025.

  • Quarterly results put Inventory Average at $590500.0 for Q4 2025, down 46.42% from a year ago — trailing twelve months through Dec 2025 was $590500.0 (down 46.42% YoY), and the annual figure for FY2025 was $700500.0, down 47.53%.
  • Inventory Average for Q4 2025 was $590500.0 at BioXcel Therapeutics, up from $482500.0 in the prior quarter.
  • Over the last five years, Inventory Average for BTAI hit a ceiling of $2.6 million in Q2 2024 and a floor of $482500.0 in Q3 2025.
  • Median Inventory Average over the past 4 years was $1.7 million (2022), compared with a mean of $1.5 million.
  • Biggest five-year swings in Inventory Average: skyrocketed 86.66% in 2023 and later tumbled 77.57% in 2025.
  • BioXcel Therapeutics' Inventory Average stood at $1.7 million in 2022, then increased by 18.16% to $2.0 million in 2023, then crashed by 45.02% to $1.1 million in 2024, then crashed by 46.42% to $590500.0 in 2025.
  • The last three reported values for Inventory Average were $590500.0 (Q4 2025), $482500.0 (Q3 2025), and $574000.0 (Q2 2025) per Business Quant data.